Skip to content

Study on the Efficacy of Individualized Transcranial Electrical Stimulation in the Treatment of Anxiety Disorders in Patients with Central Nervous System Inflammatory Demyelinating Diseases

Study on the Efficacy of Individualized Transcranial Electrical Stimulation in the Treatment of Anxiety Disorders in Patients with Central Nervous System Inflammatory Demyelinating Diseases

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115302
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-01-13
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system inflammatory demyelination patients

Interventions

Sham neuromodulation group:Sham transcranial electrical stimulation
Neuromodulation group:Individualized transcranial electrical stimulation treatment

Sponsors

Xuanwu Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The central nervous system inflammatory demyelinating diseases that meet the diagnostic criteria, such as neuromyelitis optica spectrum disorders and multiple sclerosis. 2. Hamilton Anxiety Rating Scale score > 14. 3. Age between 18 and 65 years old, regardless of gender. 4. Stable dose of immunosuppressive therapy within the past 1 month. 5. EDSS score <= 6. 6. Right-handed. 7. Consent to participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of relapse within the past 1 month. 2. History of medication adjustment or undergoing modified electroconvulsive therapy, transcranial magnetic stimulation, or other neuromodulation techniques within the past 1 month. 3. Participation in any other clinical trials within 1 month prior to enrollment or currently. 4. Presence of cochlear implants, cardiac pacemakers, or implanted brain stimulators. 5. Skin integrity impairment at the electrode placement site, or allergy to electrode gel or adhesive. 6. History of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections or other organic brain diseases. 7. Pregnant or breastfeeding women, or those planning pregnancy recently. 8. Hamilton Depression Rating Scale suicide item score >=3 or concurrent severe psychiatric disorders. 9. Concurrent severe or unstable organic diseases. 10. Unable to cooperate with treatment, follow-up, or clinical, EEG, and imaging data collection due to poor patient compliance. 11. Investigator considers the patient unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
HAMA Score Difference;

Secondary

MeasureTime frame
Safety indicators;Fatigue Severity Scale (FSS);Electrophysiological indicators;Hamilton Depression Rating Scale;

Countries

China

Contacts

Public ContactJunwei Hao

Xuanwu Hospital Capital Medical University

haojunwei@vip.163.com+86 10 8319 8707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026